What they found
TL;DR (qwen3.6:35b): MnTBAP prevented hearing loss and reversed hair cell damage caused by cisplatin in mice. This suggests MnTBAP could be a potential treatment for chemotherapy-induced deafness.
Objective: Cisplatin, a life-saving chemotherapeutic drug, causes ototoxicity. Although sodium thiosulfate is used to prevent ototoxicity in pediatric patients, no other intervention has been approved for clinical use against cisplatin-induced hearing loss. Hence, there is an urgent need to identify drugs that prevent cisplatin ototoxicity. Methods: CBA/J mice were treated with cisplatin (3 mg/kg, i.p., daily for 5 days), and MnTBAP (10 mg/kg, i.p., daily for 8 days) was used to inhibit cisplatin-induced ototoxicity. Auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs) were recorded before and after treatment to assess hearing loss, while immunohistochemistry was performed to examine hair cells and spiral ganglion neuron (SGN) loss. Results: Cisplatin treatment elevated the nitrotyrosine levels in hair cells and SGNs and increased the loss of these cells in the middle and basal cochlear regions. A negative correlation was observed between cisplatin-induced changes in the hair cell count or SGN density and nitrotyrosine levels. Cisplatin elevated the hearing thresholds and lowered the DPOAE amplitudes. However, MnTBAP cotreatment prevented the cisplatin-induced changes in the hearing sensitivity and reversed the morphological changes. Conclusion: The otoprotection observed with MnTBAP cotreatment indicates its potential as a therapeutic drug against cisplatin-induced ototoxicity.
How this applies to our program
This study validates the use of antioxidant/anti-nitrosative strategies to protect cochlear hair cells, which is directly relevant to preserving STRC function and preventing DFNB16-related degeneration. It highlights nitrotyrosine levels as a key biomarker for hair cell stress that may be modifiable in our program.
Key numbers
- CBA/J mice treated with cisplatin at 3 mg/kg daily for 5 days
- MnTBAP administered at 10 mg/kg daily for 8 days
- No other intervention besides sodium thiosulfate is currently approved for clinical use against cisplatin-induced hearing loss
Links
- biorxiv_id: https://www.biorxiv.org/content/10.64898/2026.06.04.730129
- DOI: https://doi.org/10.64898/2026.06.04.730129
Connections
[source]auto-indexed 2026-06-10 by strc-lit-watch